Google
SVRA 株価分析 — Savara Inc (Healthcare >> Biotechnology)
SVRA に関するよくある質問
SVRAのROE（自己資本利益率）は？
Savara IncのROEは-73.55%です。
SVRAの配当利回りは？
Savara Incの配当利回りは0.00%です。
SVRAの品質スコア（Quality Score）は？
当社のAIはSVRAの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
SVRAは今が買い時ですか？
当社AIのタイミングスコアは100点中55点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
SVRAはどのセクターに属しますか？
Savara IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
SVRA AI Analysis Summary
Our AI summary for SVRA: Savara Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -73.55%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 55/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 5.46
Price
-0.08
(-1.44%)
Day Change
|
|
|---|
SVRA, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.46 |
| PBV / Sector |
6.45 / 5.20
|
| Earning Per Share | -0.62 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
10.12 M
GREAT
|
| Average 1W Daily Value |
9.77 M
|
| Timing Factors |
|
28% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:32 |
| Symbol | SVRA |
| Name | SAVARA INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 204.93 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,135.30 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: The Tannery, Yardley, PA, United States, 19067
Phone: 512 614 1848
Website: https://www.savarapharma.com
Employees: 70
Sector: Healthcare >> Biotechnology
Description: Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
